Ashwani Verma
Stock Analyst at UBS
(3.79)
# 687
Out of 5,148 analysts
104
Total ratings
51.35%
Success rate
9.51%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Buy | $248 → $251 | $166.38 | +50.86% | 7 | Feb 24, 2026 | |
| HRMY Harmony Biosciences Holdings | Downgrades: Neutral | $43 → $46 | $28.90 | +59.17% | 4 | Feb 11, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $178 | $132.38 | +34.46% | 11 | Jan 23, 2026 | |
| INSM Insmed | Maintains: Buy | $223 → $215 | $146.32 | +46.94% | 1 | Jan 6, 2026 | |
| UTHR United Therapeutics | Maintains: Buy | $600 → $645 | $513.82 | +25.53% | 11 | Jan 6, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $40 | $22.81 | +75.36% | 9 | Jan 6, 2026 | |
| CORT Corcept Therapeutics | Initiates: Neutral | $95 | $35.97 | +164.11% | 1 | Dec 16, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $54 → $48 | $18.44 | +160.30% | 4 | Dec 8, 2025 | |
| BHVN Biohaven | Downgrades: Neutral | $26 → $11 | $11.81 | -6.86% | 5 | Nov 26, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $163 → $188 | $190.46 | -1.29% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $3.96 | +152.53% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $195 → $220 | $234.26 | -6.09% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $40 | $41.03 | -2.51% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $33.77 | -23.01% | 10 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $68 | $100.04 | -32.03% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $27.75 | -35.14% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $30.25 | +38.84% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $61.43 | -33.26% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.65 | -36.36% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $114.05 | -0.04% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $47.47 | -41.02% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $298.91 | -97.66% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $15.70 | -23.57% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.36 | +1,002.94% | 1 | Oct 11, 2022 |
Axsome Therapeutics
Feb 24, 2026
Maintains: Buy
Price Target: $248 → $251
Current: $166.38
Upside: +50.86%
Harmony Biosciences Holdings
Feb 11, 2026
Downgrades: Neutral
Price Target: $43 → $46
Current: $28.90
Upside: +59.17%
Neurocrine Biosciences
Jan 23, 2026
Maintains: Buy
Price Target: $188 → $178
Current: $132.38
Upside: +34.46%
Insmed
Jan 6, 2026
Maintains: Buy
Price Target: $223 → $215
Current: $146.32
Upside: +46.94%
United Therapeutics
Jan 6, 2026
Maintains: Buy
Price Target: $600 → $645
Current: $513.82
Upside: +25.53%
ACADIA Pharmaceuticals
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $22.81
Upside: +75.36%
Corcept Therapeutics
Dec 16, 2025
Initiates: Neutral
Price Target: $95
Current: $35.97
Upside: +164.11%
Legend Biotech
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $18.44
Upside: +160.30%
Biohaven
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $11.81
Upside: -6.86%
Jazz Pharmaceuticals
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $190.46
Upside: -1.29%
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $3.96
Upside: +152.53%
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $234.26
Upside: -6.09%
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $41.03
Upside: -2.51%
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $33.77
Upside: -23.01%
Jul 30, 2025
Maintains: Neutral
Price Target: $62 → $68
Current: $100.04
Upside: -32.03%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $27.75
Upside: -35.14%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $30.25
Upside: +38.84%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $61.43
Upside: -33.26%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.65
Upside: -36.36%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $114.05
Upside: -0.04%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $47.47
Upside: -41.02%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $298.91
Upside: -97.66%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $15.70
Upside: -23.57%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.36
Upside: +1,002.94%